Xu N - Search Results

1

Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.

Ma JF, Yan CL, Jia X, Zhu HJ, Yan JW, Liu MJ, Zhang DY, Liu SH, Xu N, Zhang HG, Ye L, Yu L, Wu DP, Gong WJ, Dai HP, Xue SL. Ma JF, et al. Among authors: xu n. Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132-w. Online ahead of print. Ann Hematol. 2024. PMID: 39692783 Review.

2

Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia.

Ma JF, Yan JW, Liu MJ, Yan CL, Tang XW, Qiu HY, Miao M, Han Y, Li LM, Kang LQ, Xu N, Yu Z, Tan JW, Zhu HJ, Jia X, Zhang ZZ, Wang M, Dai HP, Yu L, Xue SL, Wu DP, Gong WJ. Ma JF, et al. Among authors: xu n. Hemasphere. 2024 Oct 7;8(10):e70007. doi: 10.1002/hem3.70007. eCollection 2024 Oct. Hemasphere. 2024. PMID: 39380843 Free PMC article.

3

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.

Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Dai H, Chen J, Lin G, Wu D, Yu L. Kang L, et al. Among authors: xu n. Exp Hematol Oncol. 2020 Jun 8;9:11. doi: 10.1186/s40164-020-00166-2. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32523801 Free PMC article.

4

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia.

Chen LY, Kang LQ, Zhou HX, Gao HQ, Zhu XF, Xu N, Yu L, Wu DP, Xue SL, Sun AN. Chen LY, et al. Among authors: xu n. Transl Oncol. 2020 Nov;13(11):100838. doi: 10.1016/j.tranon.2020.100838. Epub 2020 Jul 31. Transl Oncol. 2020. PMID: 32745961 Free PMC article.

5

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W, Song B, Yin J, Li Z, Zhu X, Qu C, Liu T, Shen W, Zhu M, Yu L, Wu D, Tang X. Cui Q, et al. Among authors: xu n. J Hematol Oncol. 2021 May 25;14(1):82. doi: 10.1186/s13045-021-01092-4. J Hematol Oncol. 2021. PMID: 34034795 Free PMC article.

6

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Zhang Y, Li J, Lou X, Chen X, Yu Z, Kang L, Chen J, Zhou J, Zong X, Yang Z, Li M, Xu N, Jia S, Geng H, Chen G, Dai H, Tang X, Yu L, Wu D, Li C. Zhang Y, et al. Among authors: xu n. Front Oncol. 2021 May 25;11:664421. doi: 10.3389/fonc.2021.664421. eCollection 2021. Front Oncol. 2021. PMID: 34113569 Free PMC article.

7

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells.

Tan J, Jia Y, Zhou M, Fu C, Tuhin IJ, Ye J, Monty MA, Xu N, Kang L, Li M, Shao J, Fang X, Zhu H, Yan L, Qu C, Xue S, Jin Z, Chen S, Huang H, Xu Y, Chen J, Miao M, Tang X, Li C, Yan Z, Wu D, Yu L. Tan J, et al. Among authors: xu n, xu y. J Hematol Oncol. 2022 Apr 1;15(1):39. doi: 10.1186/s13045-022-01244-0. J Hematol Oncol. 2022. PMID: 35365211 Free PMC article.

8

Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia.

Chen LY, Gong WJ, Li MH, Zhou HX, Xu MZ, Qian CS, Kang LQ, Xu N, Yu Z, Qiao M, Zhang TT, Zhang L, Tian ZL, Sun AN, Yu L, Wu DP, Xue SL. Chen LY, et al. Among authors: xu mz, xu n. Blood Adv. 2023 Sep 12;7(17):4913-4925. doi: 10.1182/bloodadvances.2022009072. Blood Adv. 2023. PMID: 36897251 Free PMC article.

9

Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration.

Cao HY, Chen H, Liu SB, Gong WJ, Qian CS, Zhang TT, Wan CL, Huang SM, Xu N, Dai HP, Xue SL. Cao HY, et al. Among authors: xu n. Front Immunol. 2023 Apr 18;14:1181620. doi: 10.3389/fimmu.2023.1181620. eCollection 2023. Front Immunol. 2023. PMID: 37143650 Free PMC article.

10

Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C. Yan L, et al. Among authors: xu n. Cancer Med. 2021 Jan;10(2):563-574. doi: 10.1002/cam4.3624. Epub 2020 Dec 23. Cancer Med. 2021. PMID: 33356013 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,990 results

Search Page

Filters